Iceland· IS-EU/1/25/1945/001
Vevzuo
A denosumab product containing denosumabum inn, registered in Iceland by Biosimilar Collaborations Ireland Limited. The same ATC class is registered in 16 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Denosumab is registered in 16 of 19 countries.
Countries holding a registration under ATC M05BX04 (denosumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Denosumab · ATC M05BX04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of denosumab costs, country by country.
Normalised to the WHO defined daily dose (0.33 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Denosumab · price per daily dose (0.33 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.37
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Denosumabum INN
- Manufacturer
- Biosimilar Collaborations Ireland Limited
- Country
- Iceland (IS)
- ATC code
- M05BX04
- ATC class
- Denosumab
- Defined daily dose
- 0.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
262 interactions on record for denosumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Denosumab · interactions on record
262 records
- 3 severe
- 259 moderate
Most severe, free to view
- EtelcalcetideH05BX04severe
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Denosumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBILPREVDASciencepharma Sp. z o.o., Varšava
- BelgiumBilprevda 120 mgSciencePharma
- SwedenBilprevda 120 mg Injektionsvätska, lösningSciencepharma Sp. z o.o.
- PolandBilprevdaSciencePharma Sp. z o.o.
- SpainBILPREVDA 120 MG SOLUCION INYECTABLESciencepharma Sp. Z O.O.
- NorwayOsenveltCelltrion Healthcare Hungary Kft.
- United KingdomXgeva 120mg/1ml solution for injection pre-filled syringesAmgen Ltd
- SwitzerlandXGEVA 120 mg, InjektionslösungAmgen Switzerland AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Enwylma, Ponlimsi
- Liechtenstein · Bildyos, Bilprevda
- Norway · Bildyos, Bilprevda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc76b04e-a1bc-4710-a4de-fd1ee698d8b7 GET /v1/drugs/cc76b04e-a1bc-4710-a4de-fd1ee698d8b7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "M05BX04",
"marketed": false,
"strength": "120 mg",
"ma_number": "EU/1/25/1945/001",
"substance": "Denosumabum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45833"
}See everything about denosumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.